Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma

Conditions:Brain Cancer
Therapuetic Areas:Oncology
Age Range:Any - 21
Start Date:February 2008
End Date:December 2020
Contact:Genevieve Bergendahl, RN

Use our guide to learn which trials are right for you!

A Phase II Trial of Nifurtimox for Refractory or Relapsed Neuroblastoma or Medulloblastoma.

The purpose of this study is to determine whether nifurtimox in combination with
cyclophosphamide and topotecan are effective in the treatment of relapsed or refractory
neuroblastoma and medulloblastoma.

This study is being done to test the effect of a drug, nifurtimox, against neuroblastoma and
medulloblastoma in children. Nifurtimox is a drug that has been used in South America for
many years to treat a parasitic disease known as Chagas Disease. It is not approved by the
Food and Drug Administration for routine use in neuroblastoma or medulloblastoma in the
United States, but limited early observations suggest that nifurtimox may have anti tumor
activity for neuroblastoma and medulloblastoma.

From the preliminary trials of nifurtimox we have determined a safely tolerated dose of
nifurtimox to use in neuroblastoma patients (30mg/kg/day). The dose determined in the Phase I
study to be safe, will be the dose used for this study. From clinical experience in South
America, we know that children can tolerate nifurtimox when given by mouth, and it appears to
have no long-term side effects when used to treat Chagas Disease. Based on our laboratory and
animal studies, we believe that drug levels similar to those used to treat Chagas Disease may
shrink/kill neuroblastoma cells, especially when combined with other chemotherapy drugs. We
do not know whether nifurtimox will shrink/kill tumor cells effectively in children.
Therefore, the major goal of the study is to learn if nifurtimox in combination with other
chemotherapy drugs is effective in shrinking/killing neuroblastoma and medulloblastoma cells.

Inclusion Criteria:

- Age: 0-21 years at the time of diagnosis.

- Diagnosis: Histologic verification at either the time of original diagnosis or relapse
of neuroblastoma or medulloblastoma.

- Disease Status: Refractory or first or multiple relapsed neuroblastoma, or
medulloblastoma that has relapsed after, or is refractory to, a
chemotherapy-containing treatment regimen.

- Measurable disease, including at least one of the following:

- Measurable tumor by CT or MRI

- For neuroblastoma patients only, a positive MIBG (MIBG not required if subject's
neuroblastoma is previously determined to not uptake MIBG), abnormal urinary
catecholamine levels, or positive bone marrow biopsy/aspirate.

- For medulloblastoma patients only, positive CSF cytology

- Current disease state must be one for which there is currently no known curative

- A negative urine pregnancy test is required for female participants of child bearing
potential (≥13 years of age).

- Organ Function Requirements Patients without bone marrow metastases must have an ANC >
500/μl and platelet count >50,000/μl.

- Patients must have adequate liver function as defined by AST or ALT <10x normal

- Informed Consent: All patients and/or legal guardians must sign informed written
consent. Assent, when appropriate, will be obtained according to institutional

Exclusion Criteria:

- Life expectancy <2 months or Lansky score <50%

- Investigational Drugs: Patients who are currently receiving another investigational
drug are excluded from participation.

- Anti-cancer Agents: Patients who are currently receiving other anticancer agents are
not eligible. Patients must have fully recovered from the effects of prior
chemotherapy, generally at least 3 weeks from the most recent administration (6 weeks
for nitrosoureas).

- Infection: Patients who have an uncontrolled infection are not eligible until the
infection is judged to be well controlled.

- Patients who, in the opinion of the investigator, may not be able to comply with the
safety monitoring requirements of the study, or in whom compliance is likely to be
suboptimal, should be excluded.

Compensation for travel related expenses may be available
We found this trial at
San Diego, California 92123
Principal Investigator: William Roberts, MD
Phone: 858-966-8155
San Diego, CA
Click here to add this to my saved trials
800 Washington St
Boston, Massachusetts 02111
(617) 636-5000
Principal Investigator: Michael Kelly, MD
Phone: 617-636-8885
Tufts Medical Center Tufts Medical Center is an internationally-respected academic medical center – a teaching...
Boston, MA
Click here to add this to my saved trials
Orlando, Florida 32806
Principal Investigator: Don Eslin, MD
Phone: 321-841-8588
Orlando, FL
Click here to add this to my saved trials
171 Ashley Avenue
Charleston, South Carolina 29425
Principal Investigator: Jaqueline Kraveka, MD
Phone: 843-792-2957
Medical University of South Carolina The Medical University of South Carolina (MUSC) has grown from...
Charleston, SC
Click here to add this to my saved trials
Charlotte, North Carolina 28204
Principal Investigator: Javier Oesterheld, MD
Phone: 980-442-2312
Charlotte, NC
Click here to add this to my saved trials
Dallas, Texas 75235
Principal Investigator: Ted Laetsch, MD
Phone: 214-456-0004
Dallas, TX
Click here to add this to my saved trials
Grand Rapids, Michigan 49503
Principal Investigator: Deanna Mitchell, MD
Phone: 616-267-1162
Grand Rapids, MI
Click here to add this to my saved trials
Hartford, Connecticut 06106
Principal Investigator: Michael Isakoff, MD
Phone: 860-545-9337
Hartford, CT
Click here to add this to my saved trials
Hershey, Pennsylvania 17033
Principal Investigator: Valerie Brown, MD
Hershey, PA
Click here to add this to my saved trials
1319 Punahou St
Honolulu, Hawaii 96826
(808) 983-6000
Principal Investigator: Randal Wada, MD
Phone: 808-535-7169
Kapiolani Medical Center for Women and Children Hawai‘i Pacific Health is an integrated health care...
Honolulu, HI
Click here to add this to my saved trials
Houston, Texas 77030
Principal Investigator: Peter Zage, MD, PhD
Phone: 832-824-4615
Houston, TX
Click here to add this to my saved trials
Kansas City, Missouri 64108
Principal Investigator: Kathleen Neville, MD
Phone: 816-855-1977
Kansas City, MO
Click here to add this to my saved trials
Minneapolis, Minnesota 55404
Principal Investigator: Jawhar Rawwas, MD
Phone: 612-813-5913
Minneapolis, MN
Click here to add this to my saved trials
Saint Louis, Missouri 63104
Principal Investigator: William Ferguson, MD
Phone: 314-268-4000
Saint Louis, MO
Click here to add this to my saved trials
Salt Lake City, Utah 84143
Principal Investigator: Mark Fluchel, MD
Phone: 801-662-4710
Salt Lake City, UT
Click here to add this to my saved trials